A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Clinical trial NCT06504394 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06504394
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Classical Hodgkin Lymphoma Recurrent Classical Hodgkin Lymphoma Refractory Primary Mediastinal Large B-cell Lymphoma Recurrent Primary Mediastinal Large B-cell Lymphoma Refractory

Start date: 2024-10-14
Primary completion: 2028-11-08
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.